Home / Market News / $SGP
benzinga Corporate Catalyst Impact 85/100 ● neutral

SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash

Oct 1, 2026, 12:11 PM UTC · Primary ticker $SGP

SpyGlass Pharma (SGP) acquired Advanced Vision Science (AVS) for $13 million in cash, securing its intraocular lens (IOL) manufacturing capacity for its lead product candidate. This acquisition is strategically important as AVS is the current supplier for SGP's Phase 3 product and will accelerate the addition of premium lens options.

SpyGlass Pharma (SGP) has acquired Advanced Vision Science (AVS) for $13 million in cash. This is a significant strategic move for SGP as AVS is currently the manufacturer of SGP's intraocular lenses (IOLs) for its lead Phase 3 product. The acquisition secures SGP's commercial manufacturing capacity, reducing supply chain risk and accelerating its ability to integrate premium lens options. For traders, this is a positive long-term development for SGP, as it brings a critical component of its product development and commercialization in-house. While Santen (SNTDF) and Bausch + Lomb (BLCO) are mentioned, their roles as former parent and licensee, respectively, suggest a neutral impact as existing agreements will continue.

$SGP positive Secures manufacturing, accelerates product development
$SNTDF neutral Former parent, now a customer of acquired entity
$BLCO neutral Licensee of AVS technology, will continue relationship
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.